Your browser doesn't support javascript.
loading
Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre.
Nathan, Arjun; Fricker, Monty; De Groote, Ruben; Arora, Amandeep; Phuah, Yuzhi; Flora, Kiran; Patel, Sonam; Kasivisvanathan, Veeru; Sridhar, Ashwin; Shaw, Greg; Kelly, John; Briggs, Tim; Rajan, Prabhakar; Sooriakumaran, Prasanna; Nathan, Senthil.
Affiliation
  • Nathan A; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Fricker M; University College London, London, UK.
  • De Groote R; University of Newcastle, Newcastle, UK.
  • Arora A; Department of Urology, Onze Lieve Vrouw Hospital Aalst, Aalst, Belgium.
  • Phuah Y; Department of Urology, Tata Memorial Hospital, Mumbai, India.
  • Flora K; University College London, London, UK.
  • Patel S; University College London, London, UK.
  • Kasivisvanathan V; University College London, London, UK.
  • Sridhar A; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Shaw G; University College London, London, UK.
  • Kelly J; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Briggs T; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Rajan P; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Sooriakumaran P; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Nathan S; Department of Uro-oncology, University College London Hospitals NHS Foundation Trust, London, UK.
Eur Urol Open Sci ; 27: 43-52, 2021 May.
Article in En | MEDLINE | ID: mdl-33997823
ABSTRACT

BACKGROUND:

Salvage robot-assisted radical prostatectomy (sRARP) is a potential treatment option for locally recurrent prostate cancer (PCa) after nonsurgical primary treatment. There are minimal data comparing outcomes between propensity-matched sRARP and primary robot-assisted radical prostatectomy (RARP).

OBJECTIVE:

The primary objective is to compare perioperative, oncological, and functional outcomes of sRARP with primary RARP, and the secondary is to compare outcomes between sRARP after whole and focal gland therapy. DESIGN SETTING AND

PARTICIPANTS:

A 11 propensity-matched comparison was carried out of 135 sRARP cases with primary RARP cases from a cohort of 3852 consecutive patients from a high-volume tertiary centre. OUTCOME MEASUREMENTS AND STATISTICAL

ANALYSIS:

Perioperative, oncological, and functional outcomes including complication rates, positive surgical margins, biochemical recurrence (BCR), continence, and erectile dysfunction (ED) were retrospectively collected. RESULTS AND

LIMITATIONS:

There were no significant differences in patient characteristics between sRARP and primary RARP groups. In the salvage and primary groups, median (interquartile range) follow-up periods were 521 (304-951) and 638 (394-951) d, grade III-V Clavien-Dindo complication rates were 1.5% and 0% (p = 0.310), BCR rates were 31.9% and 14.1% (p < 0.001) at the last follow-up, pad-free continence rates were 78.8% and 84.3% at 2 yr (p = 0.337), and ED rates were 94.8% and 76.3% (p < 0.001), respectively. Comparing the whole and focal gland groups, BCR rates were 36.7% and 29.1% (p = 0.687) at follow-up, pad-free continence rates were 53.1% and 89.3% at 2 yr (p < 0.001), and ED rates were 98% and 93% (p = 0.214), respectively.

CONCLUSIONS:

Salvage RARP has similar perioperative outcomes to primary RARP with inferior potency rates. Post-focal therapy sRARP has similar recurrence and continence rates to primary RARP. Post-whole gland therapy, complication, and recurrence rates are higher, and there is a higher risk of urinary incontinence. PATIENT

SUMMARY:

We report the largest propensity-matched comparison of salvage robot-assisted radical prostatectomy (RARP) after focal and whole gland therapy. Salvage RARP is a feasible procedure for the treatment of locally recurrent prostate cancer in high-volume centres; however, patients should be counselled appropriately as to the different outcomes.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Urol Open Sci Year: 2021 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Urol Open Sci Year: 2021 Type: Article Affiliation country: United kingdom